Skip to main content
. 2010 Mar 11;10:92. doi: 10.1186/1471-2407-10-92

Figure 4.

Figure 4

Amounts of bFGF in supernatants of FaDu and HeLa cells measured via ELISA, treated with WX-UK1, Galardin®, and Celecoxib® as single drugs and with combinations thereof. The COX-2 inhibitor Celecoxib® displayed the greatest effects as a single drug and in combination with WX-UK1 and/or Galardin®. Triple medication was neither for FaDu nor for HeLa cells more effective than Celecoxib® alone, pinpointing that COX-2 inhibition was instrumental in the reduction of bFGF release by tumour cells.